Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 8
2019 10
2020 10
2021 32
2022 24
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. ...With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiori …
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been establi …
Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
Cowart K, Carris NW. Cowart K, et al. Expert Opin Pharmacother. 2021 Feb;22(2):163-165. doi: 10.1080/14656566.2020.1822327. Epub 2020 Sep 23. Expert Opin Pharmacother. 2021. PMID: 32962443
INTRODUCTION: A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular outcome trials (CVOTs), despite such trials being principally required to rule out excess cardiovascular risk. AREAS COVERED: Th …
INTRODUCTION: A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular …
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4. Diabetologia. 2021. PMID: 33665685 Free PMC article. Clinical Trial.
AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as …
AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event …
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.
Cherney DZI, Cosentino F, McGuire DK, Kolkailah AA, Dagogo-Jack S, Pratley RE, Frederich R, Maldonado M, Liu CC, Cannon CP; VERTIS CV Investigators. Cherney DZI, et al. Kidney Int Rep. 2023 Jan 20;8(4):746-753. doi: 10.1016/j.ekir.2023.01.011. eCollection 2023 Apr. Kidney Int Rep. 2023. PMID: 37069970 Free PMC article.
INTRODUCTION: In the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881), patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) were randomized (1:1:1) to pl …
INTRODUCTION: In the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT0198 …
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ. Scheen AJ. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Circ Res. 2018. PMID: 29748368 Free PMC article. Review.
Empagliflozin in EMPA-REG-OUTCOME (EMPAgliflozin Cardiovascular OUTCOME Events in Type 2 Diabetes Mellitus Patients) reduced major cardiovascular events, CV mortality, all-cause mortality, and hospitalization for heart failure. ...Ongoing CV outcome …
Empagliflozin in EMPA-REG-OUTCOME (EMPAgliflozin Cardiovascular OUTCOME Events in Type 2 Diabetes Mellitus Patients) re …
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, Lawrence D, Jones PLS, Liu J, Adamsons I, Dagogo-Jack S. Pratley RE, et al. Lancet Healthy Longev. 2023 Apr;4(4):e143-e154. doi: 10.1016/S2666-7568(23)00032-6. Lancet Healthy Longev. 2023. PMID: 37003273 Free article. Clinical Trial.
BACKGROUND: VERTIS CV was a randomised, double-blind, placebo-controlled, parallel-group, multicentre cardiovascular outcomes trial that evaluated the cardiovascular efficacy and safety of ertugliflozin in adults with type 2 diabetes and atheroscleroti …
BACKGROUND: VERTIS CV was a randomised, double-blind, placebo-controlled, parallel-group, multicentre cardiovascular outcomes …
Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
Tian L, Ai S, Zheng H, Yang H, Zhou M, Tang J, Liu W, Zhao W, Wang Y. Tian L, et al. Front Pharmacol. 2022 Nov 24;13:986186. doi: 10.3389/fphar.2022.986186. eCollection 2022. Front Pharmacol. 2022. PMID: 36506550 Free PMC article.
As an emerging class of glucose-lowing agents sodium glucose co-transporter 2 (SGLT2), possesses beneficial effects on cardiovascular and renal outcomes in patients with T2DM. The aim of this study is to assess the efficacy of different SGLT2 inhibitors for cardi …
As an emerging class of glucose-lowing agents sodium glucose co-transporter 2 (SGLT2), possesses beneficial effects on cardiovascular …
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
Solomon J, Festa MC, Chatzizisis YS, Samanta R, Suri RS, Mavrakanas TA. Solomon J, et al. Pharmacol Ther. 2023 Feb;242:108330. doi: 10.1016/j.pharmthera.2022.108330. Epub 2022 Dec 10. Pharmacol Ther. 2023. PMID: 36513134 Review.
Diabetes drives an increasing burden of cardiovascular and renal disease worldwide, motivating the search for new hypoglycemic agents that confer cardiac and renal protective effects. ...This review focuses on the pharmacology and pathophysiology of SGLT-2 inhibitors in pa …
Diabetes drives an increasing burden of cardiovascular and renal disease worldwide, motivating the search for new hypoglycemic agents …
Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Rev Cardiovasc Med. 2018 Jun 30;19(2):41-49. doi: 10.31083/j.rcm.2018.02.907. Rev Cardiovasc Med. 2018. PMID: 31032602 Free article.
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, and Empagliflozi …
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effec …
Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Cheng Q, Zou S, Feng C, Xu C, Zhao Y, Shi X, Sun M. Cheng Q, et al. Medicine (Baltimore). 2023 Mar 10;102(10):e33198. doi: 10.1097/MD.0000000000033198. Medicine (Baltimore). 2023. PMID: 36897734 Free PMC article.
In particular, convincing evidence on the effects of ERT on renal function and cardiovascular outcomes is needed. METHODS: We searched PubMed, Cochrane Library, Embase, and Web of Science for randomized placebo-controlled trials of ERT for T2DM published up to Augus …
In particular, convincing evidence on the effects of ERT on renal function and cardiovascular outcomes is needed. METHODS: We …
100 results